Background
SRT2379 is a selective small-molecule activator of the NAD+-dependent deacetylase,
Sirtuin 1 (SIRT1), which has broad anti-inflammatory effects in cell cultures and
rodents. The aim of the current study (EUDRACT # 2011-002266-20) was to determine
the effect of SRT2379 on the inflammatory responses in normal healthy male subjects
after exposure to LPS.
Materials and methods
This single-blind, placebo-controlled study consisted of four treatment arms (n =
8 per arm): (1) oral SRT2379 50 mg; (2) oral SRT2379 250 mg; (3) oral SRT2379 1000
mg; and (4) placebo. All subjects received a single dose of study drug on day 1 followed
by intravenous LPS 4 hours later. Laboratory parameters of inflammation along with
assessment of clinical signs, safety assessments, and pharmacokinetic measurements
were recorded at baseline and after LPS administration.
Results
SRT2379 was well tolerated. Adverse events were similar across all treatment groups
and were predominantly as expected with LPS administration. Pharmacokinetic exposures
increased in a dose-dependent manner. SRT2379 did not significantly impact cytokine
release as compared with placebo: TNFα (183.52, 177.57, 123.84 vs. 195.30 pg/ml for
groups 1, 2, 3 vs. group 4, respectively, P > 0.05), IL-6 (195.25, 237.51, 180.26
vs. 250.08 pg/ml, respectively, P > 0.05), IL-17 (3.88, 2.59, 6.42 vs. 8.09 pg/ml,
respectively, P > 0.05), IL-8 (126.11, 105.25, 110.56 vs. 108.77 pg/ml, respectively,
P > 0.05), and IL-10 (12.61, 13.03, 40.40 vs. 11.90 pg/ml, respectively, P > 0.05).
SRT2379 also had no impact on vital signs, leukocyte counts, or coagulation activation
markers compared with placebo.
Conclusions
Although SRT2379 suppresses inflammatory markers in preclinical experiments, we were
unable to demonstrate a similar impact in this human model of endotoxemia. This may
be due to potency or exposure issues, with the compound. SRT2379 terminated for further
clinical development. More promising candidates are being identified for future clinical
exploration.